Tesa supplement (tesamorelin) is a research peptide studied for visceral fat and GH release. Learn forms, dosing, safety, and what US buyers should know.
Tesa supplement is the informal name for tesamorelin, a synthetic growth hormone–releasing hormone (GHRH) analog sold online as a research peptide. Tesamorelin is not a vitamin, mineral, or herbal supplement, and it is not FDA-approved as a dietary supplement in the United States. The prescription version, Egrifta, is approved only for reducing excess visceral belly fat in adults with HIV-associated lipodystrophy.
What Is a Tesa Supplement, Exactly?
The tesa peptide is a modified 44-amino-acid version of human GHRH. It binds to GHRH receptors in the pituitary gland and prompts the body to release its own growth hormone, which then raises IGF-1 levels.
Because it is a peptide, it is fragile and poorly suited to oral delivery. The clinically studied form is an injectable powder that is reconstituted with bacteriostatic water and injected subcutaneously.
Products sold as an oral or sublingual tesa supplement are a different story. Digestive enzymes typically break peptides apart before they reach the bloodstream, so swallowed tesamorelin is unlikely to reproduce the effects seen with injections.
Reported Tesa Peptide Benefits
Reported tesa peptide benefits come almost entirely from one narrow patient group: adults with HIV-associated lipodystrophy, where daily injections reduced visceral adipose tissue in randomized controlled trials.
Those studies measured deep abdominal fat with CT scans, not weight on a scale. Body weight often stayed similar because lean mass was preserved while visceral fat dropped.
What the research does not support:
- Muscle gain or strength increases in healthy, trained adults.
- Improved athletic performance or recovery.
- Reliable fat loss in people without HIV-related lipodystrophy.
Online discussions, including reta and tesa before and after comparisons, are personal reports rather than controlled evidence. Anecdotes cannot separate a peptide's effect from diet, training, or a second compound used at the same time.
How Tesa Compares With Other Peptides
People often weigh tesamorelin against other growth hormone–related compounds before deciding what to use. The table below summarizes how they differ.
| Compound | Main mechanism | Half-life | FDA status | Typical research dose |
|---|---|---|---|---|
| Tesamorelin (tesa) | GHRH receptor agonist | ~26–38 minutes | Approved as Egrifta for HIV-associated lipodystrophy | 2 mg daily, subcutaneous |
| Ipamorelin | Ghrelin receptor agonist | ~2 hours | Not approved | 100–300 mcg per dose |
| CJC-1295 without DAC | GHRH analog | ~30 minutes | Not approved | 100 mcg per dose |
| CJC-1295 with DAC | GHRH analog bound to albumin | ~6–8 days | Not approved | 1–2 mg weekly |
| Retatrutide (reta) | GLP-1, GIP, and glucagon agonist | ~6 days | Investigational | 1–12 mg weekly in trials |
People searching for a cjc-1295 oral supplement are chasing the same goal tesa promises: growth hormone support without needles. No oral GHRH peptide has convincing published evidence of meaningful human absorption.
Blends are popular too. Threads like tesa/ipa blend reddit pair tesamorelin with ipamorelin because the two compounds hit different receptors. Stacking raises cost, injection frequency, and the odds of side effects, and no controlled trial has tested the combination.
Doses and Forms Sold in the US
In research and in the approved drug, tesamorelin is dosed at 2 mg by subcutaneous injection once daily. The 2 mg daily injection is the only tesamorelin dose with substantial human safety data.
Online listings often advertise capsules, nasal sprays, or drops at 200 mcg to 1,000 mcg. None of these formats has published human pharmacokinetic data.
Label accuracy is another problem. Independent testing of gray-market peptides has found underdosed vials, mislabeled compounds, and bacterial contamination. A certificate of analysis means little if the lab is not independent or the batch number does not match the vial.
Safety, Side Effects, and Legal Status
Tesamorelin is a prescription drug in the United States, not a legal dietary supplement ingredient, so "research use only" labels do not make a product legal to consume.
In trials, the most common side effects were injection-site reactions, muscle aches, joint pain, and peripheral swelling. Tesamorelin can raise IGF-1 and blood sugar, and it is not appropriate for people with active cancer, pituitary tumors, or uncontrolled diabetes. Other points to keep in mind:
- Long-term effects of raising growth hormone and IGF-1 in healthy adults are not established.
- Tesamorelin has not been studied in pregnancy, breastfeeding, or in people under 18.
- Quality and purity vary widely between online vendors.
Anyone considering a growth hormone–related peptide should talk with a licensed healthcare provider first, especially if they take insulin, corticosteroids, or thyroid medication.
Buying Checklist Before You Order
- Ask for a third-party certificate of analysis that includes HPLC purity and mass spectrometry results.
- Confirm the batch number on the COA matches the vial or box.
- Check whether the seller ships with cold packs; peptides degrade with heat.
- Be skeptical of sellers promising guaranteed fat loss, muscle gain, or "cures."
- Compare against FDA-approved options with your doctor before spending money online.
The Bottom Line
Tesamorelin has real human data, but only for one specific medical use and only as an injected prescription drug. Tesamorelin has no proven role as an over-the-counter supplement in the United States.
If you are curious about the tesa peptide, treat marketing claims as unproven, verify third-party testing, and speak with a healthcare professional before using anything labeled "for research use only."
Frequently Asked Questions
What is a tesa supplement?
A tesa supplement is a product marketed as tesamorelin, a synthetic growth hormone–releasing hormone analog sold as a research peptide. It is not a vitamin or herbal supplement, and the only FDA-approved version (Egrifta) is a prescription injection for HIV-associated lipodystrophy. Oral and capsule forms sold online have no published human absorption data.
Is tesamorelin FDA-approved?
Tesamorelin is FDA-approved only as Egrifta, an injectable prescription drug for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a dietary supplement, a weight-loss drug, or a performance-enhancing product. Buying it as a research chemical for personal use is a legal gray area.
How long does tesa take to work?
In clinical trials, visceral fat changes were measured over 26 to 52 weeks of daily 2 mg injections, so results were not immediate. There is no reliable timeline for unproven oral versions sold online. Fat loss also depends heavily on diet, training, and overall health.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.